Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10729144 | 0.82 | CD69 (0.41) | ALDH1A1POLBCD69HPGDHSD17B10 | |
| SCHEMBL2059355 | 0.81 | CSNK2A2 (0.49) | ALDH1A1MCL1CD69HPGDPTPRB | |
| SCHEMBL2058911 | 0.79 | THRA (0.47) | ALDH1A1POLBMCL1CD69HPGD | |
| SCHEMBL13305753 | 0.78 | PPARD (0.59) | PPARD | |
| SCHEMBL3201351 | 0.78 | KMT2A (0.55) | ALDH1A1POLBMCL1CD69HPGD | |
| SCHEMBL11570516 | 0.78 | KDM4E (0.55) | MCL1HPGDKDM4EPKMHTT | |
| SCHEMBL2059557 | 0.78 | AGBL2 (0.46) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL8240454 | 0.78 | MCL1 (0.45) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL14931907 | 0.78 | MCL1 (0.45) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL1933960 | 0.77 | S1PR1 (0.45) | ALDH1A1POLBKDM4EKMT2APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ALDH1A1 3337/4885POLB 446/4885MCL1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.